Historical record - last NADAC effective date: 12/21/2022
Product Information
INTROVALE 0.15-0.03 MG TABLET is a generic product labeled by Xiromed LLC, priced at $0.1685 per EA under NDC 70700011787. Its NADAC has been published 230 times since Aug 15, 2018.
FDA first approved this application on Sep 27, 2010. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Manufacturer
Xiromed LLCNDC
70700011787
Classification
Generic
Dosage Form
KIT
Effective Date
12/21/2022
Approval Type
Generic (ANDA)
FDA Application
ANDA079064FDA Approved
9/27/2010
TE Code
AB
On Market Since
2/1/2018
Price Statistics
The NADAC for INTROVALE 0.15-0.03 MG TABLET has been published 230 times since Aug 15, 2018, and over the history we have for it it has declined 54.1%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.1685 per EA |
|---|---|
| All-time high | $0.3739 (Aug 14, 2019) |
| All-time low | $0.1685 (Dec 21, 2022) |
| Median price | $0.2728 |
| Average price | $0.2675 |
| Largest weekly change | +52.6% (May 20, 2020) |
| Weeks tracked | 230 |
| Tracking since | Aug 15, 2018 |
1W
N/A
1M
N/A
3M
N/A
6M
N/A
1Y
N/A
3Y
N/A
5Y
-41.0%
All
-54.1%
Last surveyed Jan 4, 2023 — this NDC no longer appears in the current weekly NADAC file.
Generic Alternatives
The matcher finds 9 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 33% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Xiromed LLC manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Levonorgestrel and Ethinyl Estradiol market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of INTROVALE 0.15-0.03 MG TABLET?
The current National Average Drug Acquisition Cost (NADAC) for INTROVALE 0.15-0.03 MG TABLET, manufactured by Xiromed LLC, is $0.1685 per EA (NDC 70700011787), effective Jan 4, 2023.
How has the price of INTROVALE 0.15-0.03 MG TABLET changed over time?
Over the history we have for it, the NADAC for INTROVALE 0.15-0.03 MG TABLET has declined 54.1%. It has been tracked across 230 weekly CMS publications since Aug 15, 2018.
What are the highest and lowest recorded NADAC prices for INTROVALE 0.15-0.03 MG TABLET?
Since Aug 15, 2018, the NADAC for INTROVALE 0.15-0.03 MG TABLET has ranged from a low of $0.1685 (Dec 21, 2022) to a high of $0.3739 (Aug 14, 2019), with a median of $0.2728 per EA.
Are there cheaper alternatives to INTROVALE 0.15-0.03 MG TABLET?
Yes. 9 manufacturers publish a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, CHATEAL EQ-28 TABLET, is $0.1135 per EA — about 33% below INTROVALE 0.15-0.03 MG TABLET.
Who manufactures INTROVALE 0.15-0.03 MG TABLET?
INTROVALE 0.15-0.03 MG TABLET (NDC 70700011787) is labeled by Xiromed LLC, and CMS classifies it as a generic product.